UBE2J2

Across TCGA pan-cancer cohorts, UBE2J2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated UBE2J2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher UBE2J2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2J2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where UBE2J2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.848	0.973	<.001	26	view →
PDAC	DFS	Median	All	0.168	0.671	.004	19	view →
CCRCC	DFS	Median	III,IV	0.198	0.887	.010	14	view →
HNSC	DFS	Quartile	II,III,IV	0.813	0.552	.020	5	view →
UCEC	OS	Median	All	0.868	0.980	.032	4	view →
GBM	OS	Tertile	All	0.708	0.887	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

UBE2J2–LUAD (DFS)

Open the LUAD breakdown →